Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Modafinil may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy. The effectiveness of modafinil in relieving chemotherapy-related fatigue is not yet known.
PURPOSE: This randomized phase III trial is studying the effectiveness of modafinil in treating fatigue in patients who are receiving chemotherapy for cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Fatigue Unspecified Adult Solid Tumor, Protocol Specific |
Drug: modafinil |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Masking: Double-Blind Primary Purpose: Supportive Care |
| Official Title: | Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of The Effect Of Modafinil On Fatigue In Cancer Patients Receiving Chemotherapy |
- Efficacy to reduce fatigue during chemotherapy as assessed by the Brief Fatigue Inventory at course 4
- Relationship between depression and fatigue during chemotherapy as assessed by Fatigue Symptom Checklist, Profile of Mood States, Fatigue Severity Scale, Epworth Sleepiness Scale, Center for Epidemiologic Studies-Depression, and Mini-Mac at course 4
| Estimated Enrollment: | 837 |
| Study Start Date: | August 2002 |
| Study Completion Date: | October 2007 |
| Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- Assess the degree to which modafinil can reduce fatigue in cancer patients receiving chemotherapy.
- Assess the relationship between depression and fatigue in patients treated with this drug.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Beginning on day 5 of the second course of chemotherapy, patients receive oral modafinil once daily.
- Arm II: Beginning on day 5 of the second course of chemotherapy, patients receive oral placebo once daily.
Treatment in both arms continues until day 7 of course 4 of chemotherapy in the absence of disease progression or unacceptable toxicity.
Fatigue and quality of life are assessed on day 7 of courses 2-4 of chemotherapy.
PROJECTED ACCRUAL: A total of 837 patients will be accrued for this study within approximately 2.5 years.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Diagnosis of cancer
Concurrently receiving or has previously received chemotherapy and is scheduled for at least 3 additional courses of chemotherapy
- Each course of chemotherapy must be at least 2 weeks in duration
- No concurrent radiotherapy or interferon therapy
- Brief Fatigue Inventory question #3 "fatigue worst" score of 2 or greater 1 week after first chemotherapy course
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Not specified
Life expectancy
- At least 6 months
Hematopoietic
- Not specified
Hepatic
- No uncontrolled anemia
Renal
- Not specified
Cardiovascular
No history of clinically significant cardiac disease, including any of the following:
- Unstable angina
- Left ventricular hypertrophy
- Ischemic echocardiogram changes
- Chest pain
- Arrhythmia
- Other clinically significant manifestations of mitral valve prolapse in association with use of central nervous system stimulants (e.g., caffeine, amphetamines, or methylphenidate)
- No uncontrolled hypertension
Gastrointestinal
- Able to swallow medication
- No narrowing (pathological or iatrogenic) or obstruction of the gastrointestinal tract
Other
- No severe headaches
- No glaucoma
- No seizure disorder
- No narcolepsy
- No psychotic disorder
- No Tourette's syndrome
- No alcohol or drug abuse
- Not pregnant or nursing
- Fertile patients must use effective barrier contraception during and for at least 1 full menstrual cycle after study completion
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
Chemotherapy
- See Disease Characteristics
Endocrine therapy
- No concurrent chronic corticosteroids
Radiotherapy
- See Disease Characteristics
Surgery
- Not specified
Other
- No prior modafinil
- At least 30 days since prior regular use of psychostimulants (e.g., amphetamines, methylphenidate, or pemoline) or monoamine oxidase inhibitors (MAOIs)
- No concurrent alcohol
- Concurrent acetaminophen with codeine or hydrocodone bitartrate allowed
- Concurrent phenytoin allowed
- Concurrent warfarin for anticoagulation and low-dose warfarin (1 mg by mouth daily) for maintenance of venous access devices allowed
Contacts and Locations
Show 35 Study Locations| Study Chair: | Gary R. Morrow, PhD, MS | James P. Wilmot Cancer Center |
More Information
Additional Information:
Publications:
| Responsible Party: | Gary Morrow, Director, URCC CCOP Research Base, University of Rochester |
| ClinicalTrials.gov Identifier: | NCT00042848 History of Changes |
| Other Study ID Numbers: | CDR0000069477, U10CA037420, URCC-U2901, NCI-5952, NCI-P02-0228 |
| Study First Received: | August 5, 2002 |
| Last Updated: | March 4, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by University of Rochester:
|
fatigue unspecified adult solid tumor, protocol specific |
Additional relevant MeSH terms:
|
Fatigue Signs and Symptoms Modafinil Central Nervous System Stimulants Physiological Effects of Drugs |
Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Neuroprotective Agents Protective Agents |
ClinicalTrials.gov processed this record on May 19, 2013